Table 3.
Severity Categories of Anxiety, Depression, Insomnia, and Distress in Patients With BC
| Severity Category | Total, N (%) | Wuhan Exposure |
General Condition by Self-identification |
Treatment Discontinuationa |
BC Clinical Stage |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) |
P Value | N (%) |
P Value | N (%) |
P Value | N (%) |
P Value | ||||||||
| Yes | No | Well | Average | Poor | Yes | No | Early | Metastatic | N/A | ||||||
| GAD-7, anxiety symptoms | |||||||||||||||
| Normal | 287 (43.6) | 90 (36.4) | 197 (47.9) | .001 | 133 (49.4) | 104 (45.8) | 50 (30.9) | <.001 | 119 (41.6) | 80 (42.5) | <.001 | 175 (44.7) | 41 (35.7) | 71 (47.0) | .018 |
| Mild | 224 (34.0) | 91 (36.8) | 133 (32.4) | 93 (34.6) | 73 (32.2) | 58 (35.8) | 103 (36.0) | 75 (39.9) | 139 (35.4) | 40 (34.8) | 45 (29.8) | ||||
| Moderate | 88 (13.4) | 39 (15.8) | 49 (11.9) | 22 (8.2) | 34 (15.0) | 32 (19.8) | 36 (12.6) | 21 (11.2) | 50 (12.8) | 22 (19.1) | 16 (10.6) | ||||
| Severe | 59 (9.0) | 27 (11.0) | 32 (7.8) | 21 (7.8) | 16 (7.0) | 22 (13.6) | 28 (9.8) | 12 (6.4) | 28 (7.1) | 12 (10.4) | 19 (12.6) | ||||
| PHQ-9, depression symptoms | |||||||||||||||
| Normal | 347 (52.7) | 118 (47.8) | 229 (55.7) | .010 | 164 (61.0) | 124 (54.6) | 59 (36.4) | <.001 | 89 (40.7) | 153 (60.0) | <.001 | 221 (56.4) | 43 (37.4) | 83 (55.0) | <.001 |
| Mild | 166 (25.2) | 68 (27.5) | 98 (23.8) | 60 (22.3) | 57 (25.1) | 49 (30.2) | 62 (28.3) | 65 (25.5) | 98 (25.0) | 34 (29.6) | 34 (22.5) | ||||
| Moderate | 84 (12.8) | 32 (13.0) | 52 (12.7) | 25 (9.3) | 27 (11.9) | 32 (19.8) | 39 (17.8) | 25 (9.8) | 41 (10.5) | 22 (19.1) | 21 (13.9) | ||||
| Severe | 61 (9.3) | 29 (11.7) | 32 (7.8) | 20 (7.4) | 19 (8.4) | 22 (13.6) | 29 (13.2) | 12 (4.7) | 32 (8.1) | 16 (13.9) | 13 (8.6) | ||||
| ISI, insomnia symptoms | |||||||||||||||
| Normal | 309 (47.0) | 114 (46.2) | 195 (47.4) | .096 | 160 (59.5) | 102 (44.9) | 47 (29.0) | <.001 | 92 (42.0) | 131 (51.4) | .031 | 202 (51.5) | 39 (33.9) | 68 (45.0) | <.001 |
| Mild | 238 (36.2) | 86 (34.8) | 152 (37.0) | 83 (30.9) | 82 (36.1) | 73 (45.1) | 84 (38.4) | 89 (34.9) | 134 (34.2) | 48 (41.7) | 56 (37.1) | ||||
| Moderate | 85 (12.9) | 36 (14.6) | 49 (11.9) | 20 (7.4) | 34 (15.0) | 31 (19.1) | 34 (15.5) | 28 (11.0) | 43 (11.0) | 23 (20.0) | 19 (12.6) | ||||
| Severe | 26 (3.9) | 11 (4.4) | 15 (3.7) | 6 (2.2) | 9 (4.0) | 11 (6.8) | 9 (4.1) | 7 (2.7) | 13 (3.3) | 5 (4.4) | 8 (5.3) | ||||
| IES-R, distress symptoms | |||||||||||||||
| Normal | 112 (17.0) | 32 (13.0) | 80 (19.5) | .026 | 59 (21.9) | 36 (15.9) | 17 (10.5) | <.001 | 33 (15.1) | 47 (18.4) | .031 | 73 (18.6) | 10 (8.7) | 29 (19.2) | .004 |
| Mild | 202 (30.7) | 74 (30.0) | 128 (31.1) | 80 (29.8) | 81 (35.7) | 41 (25.3) | 59 (26.9) | 81 (31.8) | 125 (31.9) | 34 (29.6) | 43 (28.5) | ||||
| Moderate | 207 (31.5) | 84 (34.0) | 123 (29.9) | 84 (31.2) | 64 (28.2) | 59 (36.4) | 73 (33.3) | 83 (32.5) | 125 (31.9) | 33 (28.7) | 49 (32.4) | ||||
| Severe | 137 (20.8) | 57 (23.0) | 80 (19.5) | 46 (17.1) | 46 (20.2) | 45 (27.8) | 54 (24.7) | 44 (17.3) | 69 (17.6) | 38 (33.0) | 30 (19.9) | ||||
P value was calculated using the nonparametric Wilcoxon rank-sum test and Kruskal-Wallis test.
Abbreviation: BC = breast cancer; GAD-7 = Generalized Anxiety Disorder Questionnaire; IES-R = Impact of Events Scale-Revised; ISI = Insomnia Severity Index; N/A = Not provided or not available; PHQ-9 = Patient Health Questionnaire.
a
Total size is the patients who were recommended for anti-cancer treatment during COVID-19 period: n = 474.